Search

Your search keyword '"Camila Bulfoni Balbi"' showing total 5 results
Start Over Author "Camila Bulfoni Balbi" Publication Year Range Last 50 years
5 results on '"Camila Bulfoni Balbi"'

1. Immunization With Lipopolysaccharide-Activated Dendritic Cells Generates a Specific CD8+ T Cell Response That Confers Partial Protection Against Infection With Trypanosoma cruzi

Author

Lucía Biscari, Cintia Daniela Kaufman, Cecilia Farré, Victoria Huhn, María Florencia Pacini, Camila Bulfoni Balbi, Karina Andrea Gómez, Ana Rosa Pérez, and Andrés Alloatti

Subjects
dendritic cell vaccines, LPS (lipopolysaccharide), Trypanosoma cruzi (T. cruzi), activation-induced marker assay (AIM), sexual dimorphism, Microbiology, QR1-502
Abstract

Lipopolysaccharide (LPS) induces the activation of dendritic cells (DCs) throughout the engagement of toll-like receptor 4. LPS-activated DCs show increased capacity to process and present pathogen-derived antigens to activate naïve T cells. DCs-based vaccines have been successfully used to treat some cancer types, and lately transferred to the field of infectious diseases, in particular against HIV. However, there is no vaccine or DC therapy for any parasitic disease that is currently available. The immune response against Trypanosoma cruzi substantially relies on T cells, and both CD4+ and CD8+ T lymphocytes are required to control parasite growth. Here, we develop a vaccination strategy based on DCs derived from bone marrow, activated with LPS and loaded with TsKb20, an immunodominant epitope of the trans-sialidase family of proteins. We extensively characterized the CD8+ T cell response generated after immunization and compared three different readouts: a tetramer staining, ELISpot and Activation-Induced Marker (AIM) assays. To our knowledge, this work shows for the first time a proper set of T cell markers to evaluate specific CD8+ T cell responses in mice. We also show that our immunization scheme confers protection against T. cruzi, augmenting survival and reducing parasite burden in female but not male mice. We conclude that the immunization with LPS-activated DCs has the potential to prime significant CD8+ T cell responses in C57BL/6 mice independently of the sex, but this response will only be effective in female, possibly due to mice sexual dimorphisms in the response generated against T. cruzi.

Published
2022
Full Text
View/download PDF

2. Nasal immunization with a L. lactis-derived trans-sialidase antigen plus c-di-AMP protects against acute oral T. cruzi infection

Author

Maria Florencia, Pacini, Florencia Belén, González, Brenda, Dinatale, Camila, Bulfoni Balbi, Silvina Raquel, Villar, Cecilia, Farré, Giuliana, Lupi, Martín, Espariz, Víctor Sebastián, Blancato, Christian, Magni, Iván, Marcipar, and Ana Rosa, Pérez

Subjects
Protozoan Vaccines, Mice, Inbred BALB C, General Veterinary, General Immunology and Microbiology, Trypanosoma cruzi, Public Health, Environmental and Occupational Health, Neuraminidase, Mice, Infectious Diseases, Animals, Molecular Medicine, Chagas Disease, Immunization, Dinucleoside Phosphates, Glycoproteins
Abstract

The new generation of vaccines for Chagas disease, are focused to induce both humoral and cellular response to effectively control Trypanosoma cruzi parasites. The administration of vaccine formulations intranasally has the advantage over parenteral routes that can induce a specific response at mucosal and systemic levels. This study aimed to evaluate and compare the immunogenicity and prophylactic effectiveness of two Trans-sialidase (TS)-based mucosal vaccines against T. cruzi administered intranasally. Vaccines consisted of a recombinant fragment of TS expressed in Lactococcus lactis formulated in two different adjuvants. The first, was an immunostimulant particle (ISPA, an ISCOMATRIX-like adjuvant), while the second was the dinucleotide c-di-AMP, which have shown immunostimulant properties at the mucosal level. BALB/c mice were immunized intranasally (3 doses, one every two weeks) with each formulation (TS + ISPA or TS + c-di-AMP) and with TS alone or vehicle (saline solution) as controls. Fifteen days after the last immunization, both TS + ISPA or TS + c-di-AMP induced an evident systemic humoral and cellular response, as judged by the increased plasma anti-TS IgG2a titers and IgG2a/IgG1 ratio and enhanced cellular response against TS. Plasma derived antibodies from TS + c-di-AMP also inhibit in vitro the invasion capacity of T. cruzi. Furthermore, specific secretory IgA was more enhanced in TS + c-di-AMP group. Protective efficacy was proved in vaccinated animals by an oral T. cruzi-challenge. Parasitemia control was only achieved by animals vaccinated with TS + c-di-AMP, despite all vaccinates groups showed enhanced CD8

Published
2022

3. Intranasal Trans-sialidase-based vaccine against Trypanosoma cruzi triggers a mixed cytokine profile in the nasopharynx-associated lymphoid tissue and confers local and systemic immunogenicity

Author

Pacini, María F., primary, Camila, Bulfoni Balbi, additional, Brenda, Dinatale, additional, González, Florencia B., additional, Estefania, Prochetto, additional, de Hernández, María A., additional, Pamela, Cribb, additional, Cecilia, Farré, additional, Martín, Espariz, additional, Blancato, Víctor S., additional, Christian, Magni, additional, Iván, Marcipar, additional, and Pérez, Ana R., additional

Published
2023
Full Text
View/download PDF

4. Intranasal trans-sialidase-based vaccine against Trypanosoma cruzi triggers a mixed cytokine profile in the nasopharynx-associated lymphoid tissue and confers local and systemic immunogenicity

Author

María F. Pacini, Camila Bulfoni Balbi, Brenda Dinatale, Florencia B. González, Estefania Prochetto, María A. De Hernández, Pamela Cribb, Cecilia Farré, Martín Espariz, Víctor S. Blancato, Christian Magni, Iván Marcipar, and Ana R. Pérez

Subjects
Infectious Diseases, Insect Science, Veterinary (miscellaneous), Parasitology
Published
2023

5. Desarrollo preclínico de vacunas profilácticas contra la Enfermedad de Chagas basadas en Transialidasa

Author

María Florencia Pacini, Ana Rosa Pérez, Camila Bulfoni Balbi, Florencia Belén González, and Brenda Dinatale

Subjects
Chagas disease, medicine.medical_specialty, biology, business.industry, Public health, SUPERFAMILY, Disease, Vaccine antigen, medicine.disease, biology.organism_classification, Virology, Vaccination, medicine, Trypanosoma cruzi, business
Abstract

La Enfermedad de Chagas (ECh), ocasionada por el parásito flagelado Trypanosoma cruzi (T. cruzi), es una de las parasitosis de mayor impacto en la Salud Pública de Latinoamérica. Si bien actualmente existen medidas de prevención como el tamizaje en bancos de sangre, el control a las embarazadas y el control vectorial, aún se requiere de estrategias más eficaces para evitar nuevos casos. Una de estas posibles estrategias es el desarrollo de una vacuna profiláctica contra T. cruzi. Desde el descubrimiento de la enfermedad en 1909, se han evaluado diferentes vacunas experimentales, pero aún no se ha logrado el desarrollo clínico de una formulación efectiva contra el parásito. En este artículo realizamos una revisión bibliográfica acerca de las distintas estrategias de vacunación que se evaluaron hasta la actualidad y, particularmente, el uso de la enzima Transialidasa (TS) como antígeno vacunal. También abordamos distintos aspectos de la superfamilia de la TS, como la clasificación de las distintas proteínas, sus características funcionales y su rol en la infección por T. cruzi. A lo largo de 100 años se han abordado y perfeccionado una gran diversidad de estrategias vacunales contra T. cruzi, lo cual permite augurar el salto desde el campo pre—clínico al desarrollo clínico de una vacuna efectiva en un futuro cercano.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results